











































Comparative Assessment of Health Benefits of Praziquantel
Treatment of Urogenital Schistosomiasis in Preschool and
Primary School-Aged Children
Citation for published version:
Wami, WM, Nausch, N, Midzi, N, Gwisai, R, Mduluza, T, Woolhouse, M & Mutapi, F 2016, 'Comparative
Assessment of Health Benefits of Praziquantel Treatment of Urogenital Schistosomiasis in Preschool and
Primary School-Aged Children', BioMed Research International, vol. 2016.
https://doi.org/10.1155/2016/9162631
Digital Object Identifier (DOI):
10.1155/2016/9162631
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
Page 1 of 29 
 
Comparative Assessment of Health Benefits of Praziquantel Treatment of Urogenital 1 
Schistosomiasis in Preschool and Primary School-Aged Children 2 
Welcome M. Wami1,2*, Norman Nausch1,2#a, Nicholas Midzi3, Reggis Gwisai4, Takafira 3 
Mduluza5,6, Mark E.J.Woolhouse2, Francisca Mutapi1,2 4 
1Institute of Immunology and Infection Research, School of Biological Sciences, University 5 
of Edinburgh, Edinburgh, UK 6 
2Centre for Immunity, Infection and Evolution, School of Biological Sciences, University of 7 
Edinburgh, Edinburgh, UK 8 
3Department of Medical Microbiology, College of Health Sciences, University of Zimbabwe, 9 
Harare, Zimbabwe  10 
4Ministry of Health and Child Care, Murewa District Hospital, Murewa, Zimbabwe 11 
5Department of Biochemistry, University of Zimbabwe, Harare, Zimbabwe 12 
6School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, 13 
Durban, South Africa 14 
*Corresponding author:  Welcome Mkululi Wami, Institute of Immunology & Infection 15 
Research, University of Edinburgh, Ashworth Laboratories, King's Buildings, West Mains 16 
Rd, Edinburgh, EH9 3JT 17 
E-mail: wwami2002@yahoo.com 18 
#aCurrent address: Pediatric Pneumology and Infectious Diseases Group, Department of 19 
General Pediatrics, Neonatology and Pediatric Cardiology, University Children’s Hospital, 20 
Duesseldorf, Germany  21 
Page 2 of 29 
 
Abstract 22 
Schistosomiasis is a major public health problem in Africa. However, it is only recently that 23 
the burden of schistosomiasis has become recognised as a significant component impacting on 24 
the health, wellbeing and development of infants and preschool children (aged ≤5 years). A 25 
longitudinal study was conducted in Zimbabwean children to determine the effect of single 26 
praziquantel treatment on Schistosoma haematobium-related morbidity markers: 27 
microhaematuria, proteinuria, and albuminuria. Changes in these indicators were compared in 28 
1–5 years versus 6–10 years old to determine if treatment outcomes differed by age-group. 29 
Praziquantel was efficacious at reducing infection 12 weeks post-treatment: cure rate=94.6%; 30 
(95% CI: 87.9–97.7%). Infection rates remained lower 12 months post-treatment compared to 31 
baseline in both age-groups. Among children who received praziquantel, the odds of presenting 32 
with two markers of morbidity 12 weeks post-treatment were significantly lower compared to 33 
baseline; proteinuria: odds ratio, OR=0.54; (95% CI: 0.31–0.95), and albuminuria: OR=0.05; 34 
(95% CI: 0.02–0.14). Levels of microhaematuria significantly reduced 12 months post-35 
treatment, and the effect of praziquantel did not differ between the two age-groups: OR=0.97; 36 
(95% CI: 0.50–1.87). Praziquantel treatment has health benefits in preschool-aged children 37 
exposed to S. haematobium and the efficacy of praziquantel on infection and morbidity is not 38 
age-dependent.  39 
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1. Introduction 40 
Urogenital schistosomiasis, caused by the water-borne parasitic helminth Schistosoma 41 
haematobium, is an important but neglected tropical disease in Africa [1-3]. The disease causes 42 
significant paediatric health problems in endemic regions, with negative impacts on child 43 
health and development. In S. haematobium infections, damage caused by the parasite eggs 44 
lodged in tissues or exiting the body via the urine can result in bladder or urinary tract 45 
pathology, often characterized by blood in urine (macro- or microhaematuria), painful urination 46 
(dysuria) and proteinuria [4, 5]. High levels of albumin in urine have also been shown to be 47 
strongly correlated with urinary tract pathology due to S. haematobium infection [6]. Chronic 48 
infection with schistosomes in children is associated with complications such as anaemia, 49 
malnutrition, growth retardation, reduced physical fitness, and impaired memory and cognition 50 
[7, 8]. Infection and morbidity are controlled by treatment of infected individuals with the 51 
antihelminthic drug, praziquantel (PZQ) [9, 10]. Delayed or a lack of intervention can result in 52 
more severe and irreversible forms of morbidity including urinary bladder cancer (squamous 53 
cell carcinoma) and chronic kidney disease, which may eventually result in death [11-13].  54 
In several countries implementing schistosomiasis control programmes, the control strategies 55 
follow the directive by the World Health Assembly resolutions (WHA 54.19 and WHA 65.21)  56 
in 2001 [9], involving regular school based de-worming using PZQ, aimed at reducing 57 
morbidity and promoting child health. However, a growing number of studies from Africa have 58 
shown that preschool children (aged ≤5 years old) are also at high risk of schistosomiasis 59 
through passive exposure to infection whilst being bathed with infested water [14-18]. 60 
Furthermore, recent studies have also shown that PZQ treatment of schistosome infection is 61 
safe in preschool children [16, 19]. These findings have led to a new major recommendation 62 
by the World Health Organization (WHO) in 2010, stating that preschool-aged children should 63 
be considered for treatment through the regular health services as well as in ongoing public 64 
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health intervention programmes [20]. This recent development in schistosomiasis control 65 
policy has heightened the need for a clear understanding on the health benefits of PZQ beyond 66 
the immediate reduction in infection levels in preschool-aged children in order to improve the 67 
effectiveness of interventions targeting this age group [21].  68 
In a previous study in this population, we showed that, based on attributable fractions, 69 
albuminuria measured as the urine albumin-to-creatinine ratio (UACR) was the most reliable 70 
tool for detecting schistosome-related morbidity, followed by proteinuria and microhaematuria 71 
determined by dipsticks, visual urine inspection, questionnaires, and lastly clinical examination 72 
[22].  Thus, in this current study we focused on albuminuria, proteinuria and microhaematuria. 73 
The aim of this study was to evaluate the immediate health benefits of PZQ in preschool-aged 74 
(1–5 years) children endemically exposed to S. haematobium at 12 weeks post-treatment, and 75 
to determine if a single dose of PZQ (40 mg/kg) has sustainable impact on the health status of 76 
these children by assessing changes in infection rates and levels of schistosome-related 77 
morbidity markers (microhaematuria, proteinuria and albuminuria) 12 months after treatment. 78 
Furthermore, we sought to determine whether the impact of PZQ treatment outcome is age-79 
dependent by comparing these indicators in preschool and primary school-aged (6–10 years) 80 
children in the same population. The findings of our present study provide an operational 81 
recommendation for future studies on the control of paediatric schistosomiasis, whilst also 82 
giving further insights into the health benefits of antihelminthic treatment in preschool-aged 83 
children.  84 
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2. Materials and Methods 85 
2.1 Ethics Statement and Consent 86 
Prior to commencing the study, ethical clearance was obtained from the Medical Research 87 
Council of Zimbabwe (Approval Reference: MRCZ/A/1615). In addition, the study received 88 
institutional approval from the University of Zimbabwe. Permission to conduct the study was 89 
obtained from the Provincial Medical Director, the District Educational Officer, and heads of 90 
schools in the study area. Study objectives and procedures were fully explained to the 91 
community, parents/guardians, teachers, and primary school-aged children in the local 92 
language, Shona. Samples were collected only after obtaining informed written parental 93 
consent and study participants’ oral assent. Participants were permitted to withdraw from the 94 
study at any point without further obligation.  95 
2.2 Study Site 96 
The study was undertaken in Murewa district, in the north-east of Zimbabwe (31⁰90'E; 97 
17⁰63'S) where S. haematobium is endemic. The area has low transmission of S. mansoni and 98 
soil-transmitted helminths (STH) as previously reported in other studies [23, 24]. In a nation-99 
wide survey among school-aged children in 2010 in Zimbabwe, Midzi et al [25] reported a 100 
schistosomiasis prevalence of 31.2% in Murewa district based on parasitological diagnostic 101 
methods. To confirm this reported level of schistosome infection in the community in our study 102 
site, we initially conducted a pilot study among primary school-going children (aged 6–10 103 
years old) as per sampling guidelines and recommendations by the WHO [26, 27]. A random 104 
sample of 50 compliant children from the two schools in the study area (25 from each school) 105 
was screened for schistosome infections by parasitology. Children found positive for infection 106 
during the pilot survey were treated with the recommended single dose of PZQ (40 mg/kg), but 107 
were then ineligible for participation in the main study.  108 
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2.3 Study Design and Population 109 
The longitudinal study was designed to relate changes in the levels of infection and markers of 110 
schistosome-related morbidity to the two age groups of children (1–5 years vs. 6–10 years) 111 
conducted over a period of 12 months. There were two aspects to the longitudinal study design 112 
investigating; (i) the short term effects of PZQ treatment which measured the morbidity 113 
markers and infection levels before treatment/baseline (February–March 2012) and 12 weeks 114 
(May 2012) after treatment ; the workflow for this aspect of the study is shown in Figure 1a 115 
and, (ii) the longer-term effects of PZQ treatment which measured the morbidity markers and 116 
infection levels before treatment and 12 months (March 2013) after treatment; the workflow 117 
for this aspect of the study is shown in Figure 1b. The 388 children who received treatment at 118 
baseline (Figures 1a/b) participated in both aspects of the study, so that the 303 children whose 119 
infection status was confirmed egg negative at the 12 weeks efficacy check survey formed the 120 
treated cohort for follow up at 12 months (Figure 1b). Untreated children (Figure 1a) were not 121 
followed up beyond 12 weeks. Children were recruited from two primary schools (typically for 122 
6–10 years olds) and the early childhood development centres (ECDs) for preschool-aged 123 
children located within each of the primary schools. The schools also served as recruitment 124 
centres for children aged between 1–5 years not enrolled in any of the educational programmes 125 
in the study area who were also invited for enrolment to participate in this study.  The villages 126 
within the study sites share the same river systems, therefore the transmission dynamics in the 127 
two schools (and associated ECDs) were similar.  128 
2.4 Screening and Follow-up Criteria 129 
In order to be included in this study at baseline, children had to meet the following criteria: (i) 130 
had been life-long (i.e., permanent) residents of the study area, (ii) had no prior history of 131 
antihelminthic treatment (assessed by questionnaires administered to parents/guardians of all 132 
children), and (iii) had provided at least two urine samples collected on consecutive days for 133 
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the parasitological diagnosis of S. haematobium infection. For potential exclusion, children 134 
were assessed to identify: (i) pre-existing medical conditions or clinical symptoms of 135 
tuberculosis, any form of fever, or other signs of being unwell upon examination by study 136 
clinicians, (ii) recent major operation or illness as reported by parents/guardians, and (iii) 137 
infection with any of STHs or S. mansoni. No soil transmitted helminth infections were 138 
detected in this study cohort and 27 children positive for S. mansoni were offered PZQ treated 139 
but excluded based on this criterion. Participating children that were found egg-positive for S. 140 
haematobium at the 12 week efficacy check were treated with 40 mg/kg praziquantel but 141 
excluded from further follow-up to ensure that in addition to new infections, only ‘true’ re-142 
infection was measured. Children who met the eligibility criteria, with informed consent, but 143 
would not accept treatment on religious grounds, or were absent on treatment survey days but 144 
voluntarily remained in our study cohort at 12 weeks effectively became untreated controls for 145 
evaluating the effect of treatment on schistosome-related morbidity markers. At the end of the 146 
study (12 months), PZQ treatment was offered to all children diagnosed egg positive for 147 
infection. 148 
2.5 Parasitological Methods 149 
At all survey time points, urine samples were collected on three consecutive days for 150 
parasitological examinations. S. haematobium infection was detected by microscopic 151 
examination of the parasite eggs in urine, processed using the standard urine filtration method 152 
[28]. For each child, infection intensity was expressed as the arithmetic mean of egg counts per 153 
10 mL urine of samples collected on consecutive days. At least two stool samples were also 154 
collected over three consecutive days, processed using the Kato-Katz method [29], and 155 
subsequently examined by microscopy for the diagnosis of S. mansoni. In a previous study we 156 
also determined the infection status of the children by serology, details of this methodology are 157 
described elsewhere [30].   158 
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2.6 Assessment of Morbidity Markers 159 
Three urinary markers; microhaematuria, proteinuria and albuminuria identified in our earlier 160 
published study [22] were chosen for investigating the effect of PZQ treatment on schistosome-161 
related morbidity in this present study. Urine samples collected between 10:00h and 14:00h 162 
and processed on the first day of each survey time point were examined for microhaematuria 163 
and proteinuria, detected by dipstick reagent strip test (Uripath, Plasmatec, UK). Briefly, the 164 
reagent end of the test strip was dipped into fresh, well-mixed urine for 40 seconds. Upon 165 
removal, the test area was compared with a standard colour chart following the manufacturer's 166 
guidelines and the dipstick test results were calibrated as either positive or negative. To assess 167 
the stability of dipstick urinalysis [31], repeated tests (at least two repetitions) were performed 168 
on a random sample (n=189) of urine specimens, allowing for time delay of up to 5 minutes 169 
between each of the repeated readings. There were no marked differences observed between 170 
repeated tests to suggest potential instabilities of urinalysis due to delays in dipstick testing. 171 
No observer bias was suggested by the urinalysis results when comparing the visually recorded 172 
dipstick readings to those read automatically using Siemens' CLINITEK Status + Analyzer 173 
(Bayer, UK). CLINITEK Microalbumin Reagent Strips (Bayer, UK) were used to determine 174 
the urine albumin-to-creatinine ratio (UACR) threshold levels (normal: UACR< 3.4 mg/mmol, 175 
abnormal: UACR ≥3.4 mg/mmol, or high abnormal: UACR ≥33.9 mg/mmol), as read from the 176 
instrument following the manufacturer’s guidelines. For each child, albuminuria as a marker 177 
of schistosome-related morbidity associated with urinary tract pathology was defined as a 178 
positive test for high abnormal UACR in each of the fresh urine samples examined [4].   179 
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2.7 Praziquantel Treatment  180 
After collection of samples at baseline, compliant children were offered treatment with PZQ at 181 
the standard oral dosage of 40 mg/kg body weight. The PZQ drug was procured from 182 
Pharmaceutical and Chemical Distributors (Pvt) Ltd., Harare, Zimbabwe, a company registered 183 
and licensed to sell the antihelminthic drug in Zimbabwe. The tablets were swallowed with 184 
squash juice to reduce their bitter taste and a slice of bread to reduce the side effects of PZQ 185 
[16, 32]. For the very young children, the tablets were crushed according to the current 186 
recommendation by the WHO [20]. 187 
2.8 Sample Size Calculations 188 
The relationship between schistosomiasis infection levels and indicators of morbidity is still 189 
unclear. We thus based our sample size calculations under the expectations that PZQ treatment 190 
reduces re-infection rates by more than 50% after 12 months. These expected effects are 191 
consistent with data from previous studies [16, 25], and are of sufficient magnitude to be of 192 
practical interest. Allowing for dropouts, our simulation studies using StatXact v.8 (Cytel 193 
Software Corp, Cambridge, MA, USA) indicated that the sample sizes shown in Figures 1a and 194 
1b will give us more than 80% power to detect age-related and treatment-related differences 195 
with significance level, α = 0.05.  196 
2.9 Data Management and Statistical Analysis 197 
Infection intensity was log-transformed: log10(egg count + 1) to meet the distributional 198 
assumptions of parametric test-statistics. Treatment efficacy against S. haematobium infection 199 
was assessed by means of cure rates (CR) and egg reduction rates (ERR), defined as: CR= 200 
(number of children S. haematobium egg-negative at 12 weeks post-treatment/ number of 201 
children confirmed egg-positive at baseline) X 100; ERR= (arithmetic mean egg count at 202 
baseline –arithmetic mean egg count at 12 weeks post-treatment/ arithmetic mean egg count at 203 
baseline) X 100. The 95% confidence intervals (95% CI) for the ERR were calculated using a 204 
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bootstrap resampling method with 1000 replicates in R 3.1.2 (R Development Core Team, 205 
Vienna, Austria), package=“eggCounts’’. A Chi-square test (𝜒2) or the Fisher's exact test in 206 
the case of small expected frequencies (n<5) was used for comparison of infection prevalence 207 
and cure rates between the two age groups. For infection intensity, a paired t-test was used to 208 
compare levels of infection pre- vs. post-treatment.For each of the three urinary markers of 209 
schistosome-related morbidity (microhaematuria, proteinuria, and albuminuria), the outcome 210 
of interest was a dichotomous variable indicating whether the child presented with morbidity 211 
or not at a given time point (morbidity: 0=negative; 1=positive). The main predictor variables 212 
included the host factors sex (male vs. female) and age group (1–5 years vs. 6–10 years), 213 
treatment group (untreated vs. PZQ treated) and time (pre- vs. post-treatment). To assess the 214 
effect of treatment (pre/post) on morbidity markers, we used the method of generalized linear 215 
mixed model (GLMM) with a random effect to account for the correlation between children 216 
recruited from the same primary school/ECD as described earlier.  The model-building process 217 
involved backward stepwise inclusion of the main effect covariate terms and their two-way 218 
interactions. All statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, 219 
NC, USA). The GLMMs were run using “PROC GLIMMIX” with a logit-link function to 220 
model the log odds of the probability of a child presenting with  morbidity marker upon 221 
examination, and the parameter estimation was implemented using the method of penalized 222 
quasi-likelihood to account for over-dispersion [33]. Comparisons for the binary morbidity 223 
marker responses between different sub-groups of predictor variables were implemented using 224 
the contrast options within the “GLIMMIX” procedure. In all the analyses, multiple pairwise 225 
comparisons were adjusted for family-wise type I error using the less conservative (i.e. has low 226 
rate of false negatives) simulation-based approach [34]. The level of significance was set at 227 
P<0.05 for all the statistical tests performed. To aid the interpretation of the relative effect of 228 
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treatment on infection levels and morbidity markers, standard errors (SE), 95% CI and adjusted 229 
odds ratios (OR) were presented along with the significance test statistics.   230 
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3. Results 231 
3.1 Demographic Characteristics and Pre-treatment Infection Levels 232 
Of the eligible children screened at baseline (see Figure 1a and Figure 1b), a total of 508 233 
children were included in the study, with 388 receiving PZQ treatment and 120 remaining 234 
untreated. Infection prevalence in the 508 children was 24.2% (95% CI: 20.5–28.0%), 6.7% 235 
(95% CI: 3.5–9.9%) in 1–5 year olds (n=239) and 39.8% (95% CI: 33.9–45.7%) in 6–10 year 236 
olds (n=269). In a subgroup of the 508 children, serological analysis showed that 63.0% (95% 237 
CI: 57.7–68.2%) of the children were seropositive for S. haematobium egg antigens, 39.8% 238 
(95% CI: 33.9–45.7%) were 1–5 year olds (n=131) and 79.1% (95% CI: 73.4–84.8%) were 6–239 
10 year olds (n=201). The characteristics of the current study population are shown in Table 1. 240 
When considering the children treated at baseline and followed up at 12 weeks (n=303, Figure 241 
1a), the baseline infection prevalence determined by parasitology was 30.4% (95% CI: 25.2–242 
35.6%) compared to 18.0% (95% CI: 8.1–28.0%) in the children who were not treated at 243 
baseline (n=61, Figure 1a) but voluntarily remained in the study at 12 weeks.  244 
3.2 Treatment Efficacy on Infection Levels at 12 weeks Post-treatment 245 
Twelve weeks after treatment, PZQ was efficacious at reducing S. haematobium infection 246 
among treated children in both age groups, as shown by high cure and egg reduction rates in 247 
Table 2. The overall cure and egg reduction rates in our study were 94.6%; (95% CI: 87.9–248 
97.7%) and 97.9% (90.6–99.5%), respectively. There was no significant difference (Fisher’s 249 
exact test, P=0.481) in cure rates between the two age groups (1–5 years vs. 6–10 years) 12 250 
weeks after treatment shown in Table 2. 251 
3.3 Effect of Treatment on Infection/re-infection rates at 12 months Post-treatment 252 
Following initial treatment at baseline, children who had successful curative treatment were 253 
further followed-up to determine the re-infection rates and proportion of new infections 12 254 
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months after intervention. Table 3 shows the percentage proportion of treated children who 255 
were infected at baseline and then got re-infected (n=7) and those newly infected (n=11) within 256 
12 months following treatment. The infection prevalence 12 months after treatment was low 257 
(i.e. <10% according to WHO classifications) as shown in Table 3. Furthermore, the proportion 258 
of infected/re-infected children did not significantly differ (χ2=0.37; P=0.542) between the two 259 
age groups: 1–5 years, n=5: 6.3% (95% CI=2.7–13.8%) vs. 6–10 years, n=13: 8.5% (95% CI: 260 
4.8–14.4%). Similarly, the mean infection intensity level 12 months post-treatment 261 
(mean=0.74 egg/10 mL urine; SE=0.27) was significantly lower (paired t-test=-7.95; P<0.001) 262 
compared to the baseline level (mean=14.3 egg/10 mL urine; SE=4.63) in this study, with all 263 
egg-positive children carrying light infection intensities only. 264 
3.4 Effect of Treatment on Morbidity Markers at 12 weeks Post-treatment 265 
The effect of PZQ on levels of morbidity markers was assessed in those children that had 266 
successfully cleared the infection at 12 weeks. Praziquantel significantly reduced levels of 267 
proteinuria and albuminuria 12 weeks after treatment (Figure 2). In addition, the odds of 268 
children who received praziquantel presenting with each these markers of morbidity 12 weeks 269 
after treatment were lower compared to the odds before treatment, adjusting for sex and age 270 
group; proteinuria: OR=0.54; (95% CI: 0.31–0.95) and albuminuria: OR=0.05; (95% CI: 0.02–271 
0.14). Furthermore, all the treated children aged 1–5 years successfully cleared albuminuria at 272 
12 weeks and a significant reduction from baseline was observed among the 6–10 year olds 273 
(Figure 2). A mild decrease in the levels of microhaematuria among the treated preschool-aged 274 
children was also observed, however, these changes were not significant. Changes from 275 
baseline in the levels of the three markers of schistosome-related morbidity in untreated 276 
children at 12 weeks were not significant (Figure 2).   Furthermore, when evaluating the overall 277 
changes in morbidity markers among the treated group (pre- vs. post-treatment) compared to 278 
the changes in untreated children, it was observed that the odds of albuminuria were lower: 279 
Page 14 of 29 
 
OR=0.43 (95% CI: 0.19–0.98; P=0.045), adjusting for sex and age group.3.5 Effect of 280 
Treatment on Morbidity Markers at 12 months Post-treatment 281 
Following curative treatment of infection at 12 weeks, as assessed by parasitology, children 282 
were further followed-up and examined for morbidity at 12 months. Our analyses showed that 283 
when morbidity marker levels were investigated relative to baseline levels, microhaematuria 284 
significantly dropped in both age groups at 12 months after treatment (Figure 3). Furthermore, 285 
the results of GLMMs weighted by age-group sample sizes showed that the odds of treated 286 
children presenting with microhaematuria 12 months post-treatment did not significantly differ 287 
between 1–5 years vs. 6–10 years old children: OR=0.97; (95% CI: 0.50–1.87). In the case of 288 
proteinuria and albuminuria at 12 months, there was a significant reduction relative to baseline 289 
in the older age group, but not in 1–5 year olds (Figure 3). This was despite the initial reduction 290 
in albuminuria levels in this age group observed 12 weeks after treatment, as was shown in 291 
Figure 2.   292 
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4. Discussion 293 
Praziquantel is currently the recommended antihelminthic drug of choice by the WHO for 294 
treating schistosomiasis, and is effective against all the major schistosome species infecting 295 
humans [9]. As of present, the health benefits of PZQ treatment in children aged 5 years and 296 
below has not yet been extensively evaluated. Thus, in this study we sought to determine if 297 
PZQ treatment improves the current health status of children aged 1–5 years old. The pre-298 
treatment infection levels reported in this study confirmed that preschool-aged children are 299 
exposed to schistosome infection, in concurrence with findings from other recent studies [16, 300 
30], and further support the premise that if left untreated, these children are at an increased risk 301 
of developing severe morbidity that may cause serious health consequences and negatively 302 
impact their future quality of life [18, 35, 36]. In this study there were few children aged 303 
between 1 and 5 years who were excreting parasite eggs, but the prevalence of 6.7% is typical 304 
in this age group. More importantly, we and others [17, 30], have shown that the widely utilised 305 
egg count diagnostic method greatly underestimates infection prevalence in young children. 306 
Indeed, in a seroprevalence study of a subgroup of the 508 children in this group, the 307 
seropositive rate for S. haematobium egg antigen was 39.8% in 1–5 year olds.  Thus, it is 308 
important to investigate the effects of treatment on other markers with health implications other 309 
than just the egg counts.  310 
Our study results at 12 weeks after chemotherapy showed that a single standard dosage of PZQ 311 
was efficacious against S. haematobium infection in both 1–5 year olds and 6–10 year olds. 312 
The ranges of cure and egg reduction rates observed in this study for both age groups are 313 
consistent with data reported in the literature that have also shown high PZQ treatment efficacy 314 
within six weeks after treatment [16, 37, 38]. More interestingly, our study further revealed 315 
that PZQ treatment was effective in reducing S. haematobium infection levels in preschool-316 
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aged children as was observed in their older counterparts (6–10 year olds), further supporting 317 
their inclusion in current schistosomiasis control programmes [20, 39]. 318 
Infection prevalence remained lower 12 months after treatment compared to baseline levels, 319 
and the proportion of infected/re-infected children did not significantly differ between the two 320 
age groups. In addition, our study showed significant reductions in mean S. haematobium egg 321 
counts 12 months after treatment compared to baseline. These results are in agreement with 322 
those of previous studies from different endemic areas that also reported a lower risk of S. 323 
haematobium re-infection after annual school-based treatment [40, 41], indicative of the benefit 324 
of treatment in the prevention of infection through reduced parasite transmission at population 325 
level [40]. This combination of findings on the benefits of PZQ chemotherapy against infection 326 
provides some strong support for the need for inclusion of preschool-aged children in ongoing 327 
schistosomiasis control programmes, in order to increase the effectiveness of coverage of those 328 
infected, also recently highlighted in a study by Garba et al [1]. 329 
Since schistosome-related morbidity is cumulative and progressive [42], decrease in current 330 
morbidity can reduce the long-term schistosomiasis sequelae. At 12 weeks after the first 331 
treatment, there was a significant decrease in the levels of the morbidity markers proteinuria 332 
and albuminuria in children successfully treated for infection. Interestingly, the effects of 333 
treatment were found not to be age-related, with microalbuminuria completely reversed in 334 
preschool-aged children at 12 weeks. The study also revealed that the prevalence of morbidity, 335 
diagnosed by presence microhaematuria, declined slowly, with a significant reduction observed 336 
after 12 months post-treatment. Our findings on the immediate health benefits of PZQ 337 
treatment were further reinforced by the results of the untreated group, showing no significant 338 
change in the levels of markers of schistosome-related morbidity at the 12 weeks follow-up.  339 
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The results showing persistently high levels of microhaematuria 12 weeks after treatment differ 340 
from some published studies that reported a considerable drop in microhaematuria within eight 341 
weeks after PZQ treatment [5, 43, 44]. However, most of these studies focused on older school-342 
aged children who may have developed chronic infection. The high sensitivity of dipstick 343 
reagent strips in detecting microhaematuria, as previously reported [45], could also be one 344 
possible reason for these findings in our study. Another possible explanation for this delayed 345 
decrease in microhaematuria may be that most of the observed microhaematuria in these 346 
children may have likely been due to other health conditions other than schistosome infection. 347 
In an earlier study of this population we showed that the proportion of microhaematuria 348 
attributable to schistosome infection was less than that of albuminuria and proteinuria [22]. 349 
These results therefore need to be interpreted with caution. 350 
One of the main objectives of schistosomiasis control programmes in endemic areas is 351 
preventative chemotherapy to combat the development of severe morbidity [20]. Thus, more 352 
efforts are needed to ensure that the immediate health benefits of chemotherapy are sustained 353 
in the targeted populations for effective control [1]. The current study revealed that a single 354 
PZQ treatment had sustained effects on the reduction of schistosome-related morbidity, as 355 
indicated by the levels of urinary markers that remained low 12 months after treatment. 356 
Furthermore, it is interesting to note that both the preschool and primary-school age groups 357 
demonstrated improved health beneficial treatment effect in terms of reduced morbidity burden 358 
measured by microhaematuria 12 months following single treatment with PZQ. In view of the 359 
current observations showing no age-related differences in treatment efficacy, it is thus 360 
practically possible for control programmes in endemic areas targeting preschool-aged children 361 
to be implemented using the existing treatment strategies designated for school-aged children.  362 
Nevertheless, our study has limitations that must be considered when interpreting these results. 363 
Firstly, participation of the controls was on a voluntary basis for ethical reasons, hence leading 364 
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to a small sample size for this group. This could have introduced additional uncertainties in the 365 
levels of infection and schistosome-related morbidity markers leading to a potential bias in the 366 
effects of treatment reported in this study. To minimise the effects of this potential bias, a 367 
random effect was included in the statistical models to account for some of the uncertainty. 368 
Secondly, since the majority of the children carried light infections, the parasitological cure 369 
rates may have been overestimated. Nonetheless, it is reassuring that efficacy rates reported in 370 
our study were comparable with those observed from other previous epidemiological studies 371 
in the same age range [1, 16]. 372 
 5. Conclusions 373 
In this study, we have demonstrated that praziquantel treatment does not only effectively 374 
reduces S. haematobium infection levels, but also the levels of related morbidity in both 375 
preschool and primary school-aged children, with the reduction in some morbidity markers 376 
recorded within 12 weeks of treatment being sustained over a period of one year. In conclusion, 377 
praziquantel treatment has immediate health benefits in preschool-aged children exposed to S. 378 
haematobium, and the effects of praziquantel on infection and morbidity measures is not age 379 
dependent. These findings are important for practitioners, policy makers and stakeholders 380 
involved in the control of schistosomiasis and timely because of the current global drive to 381 
address the health iniquity created by the paucity of information on the impact of praziquantel 382 
treatment on schistosome-related morbidity in children aged 5 years and below.  383 
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List of Tables 539 
Table 1: Demographic characteristics of the study cohort followed-up at 12 weeks and 12 540 
months post-treatment with complete parasitology data for S. haematobium infection. 541 
    Treated group Untreated controlsa 
Variable Characteristic 
Baseline/12 
weeks 12 months Baseline/12 weeks 
Sample size n 303 233 61 
Sex  M/F 142/161 108/125 29/32 
Age (years) 
Mean age 
(range) 6.6 (1–10) 6.9 (1–10) 4.9 (1–10) 
  Median  6 7 5 
Age group, n (%) 1–5 years 109 (36%) 80 (34%) 40 (66%) 
  6–10 years 194 (64%) 153 (66%) 21 (34%) 
aThe data on voluntary untreated controls was only collected at baseline and 12 weeks follow-542 
up surveys. 543 
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Table 2: Treatment efficacy of a single dose of praziquantel (40 mg/kg) against S. haematobium infection by age group at 12 weeks post-544 
treatment. SE=standard error; CR=cure rate; ERR=egg reduction rate, with 95% confidence intervals (95% CI). 545 















 (95% CI) 
ERRa  
(95% CI) 
1–5 years 109 8 2.7 (1.79) 8 0.0 (–) 100.0% (67.7–100.0%) 100.0%  (–) 
6–10 years 194 84 28.8 (8.40) 79 0.6 (0.45) 94.0% (86.8–97.4%) 97.9% (89.9–99.5%) 
aThe 95% confidence intervals for the ERRs were calculated using a bootstrap resampling method with 1000 replicates.546 
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Table 3: Levels of S. haematobium re-infection and new infection rates among treated 547 
children in the study 12 months following treatment with as single dose of 40 mg/kg 548 
praziquantel. Percentage proportions, with 95% confidence intervals (95% CI) of children 549 
infected with S. haematobium detected by parasitology.  550 
    
12 months post-treatment S. haematobium 
infection/re-infection rate 
Infection group Sample size (n) Number egg-positive Prevalence (95% CI) 
Re-infectionsa  76 7 9.2% (4.5–17.8%) 
New infectionsb 157 11 7.0% (4.0–12.1%) 
aEgg-positive at baseline and re-infected 12 months after treatment. 551 
bUninfected at baseline, and found egg-positive 12 months after treatment.552 
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List of Figure Legends 553 
Figure 1a: Study design flowchart showing the number of children included for the final 554 
analysis to assess the effect of praziquantel treatment efficacy 12 weeks after treatment. 555 
Participants who preferred not to receive treatment but voluntarily remained in the study at 12 556 
weeks were utilised as untreated controls. 557 
Figure 1b: Study design flowchart to assess the effect of praziquantel 12 months after 558 
treatment.  559 
Figure 2: Effect of praziquantel (PZQ) treatment on the levels of urinary markers of 560 
schistosome-related morbidity 12 weeks after treatment. (A) Microhaematuria, (B) 561 
Proteinuria, and (C) Albuminuria. The error bars indicate the 95% confidence intervals. The 562 
P-values for pairwise comparisons are from generalized linear mixed models investigating the 563 
probability of a child presenting with morbidity marker pre- vs. post-treatment adjusted for sex 564 
and age group. Significant P-values are highlighted in bold. *Contrast P-value determined 565 
using the Binomial exact test. 566 
Figure 3: Effect of praziquantel treatment on levels of urinary markers of schistosome-567 
related morbidity 12 months post-treatment.  (A) Microhaematuria, (B) Proteinuria, and (C) 568 
Albuminuria.  Error bars indicate 95% CI and the P-values for pairwise comparisons are from 569 
the generalized linear mixed models investigating the probability of a child presenting with 570 
morbidity markers pre- and post-treatment, adjusted for sex and age group. Significant P-571 
values are highlighted in bold. 572 
